Back to search results

Study of Izalontamab Brengitecan for EGFR-mutated Non-small Cell Lung Cancer

This study is testing a new treatment called Izalontamab Brengitecan (BMS-986507) against standard chemotherapy (Carboplatin or Cisplatin plus Pemetrexed) for people with non-small cell lung cancer. You might be able to join if your cancer has specific changes in the EGFR gene (exon 19 deletion or L858R mutation) and has gotten worse after treatment with a third-generation EGFR-TKI (like osimertinib). Researchers will look at how well Izalontamab Brengitecan works to stop the cancer from growing (Progression-Free Survival) and to find the best dose. The study plans to enroll 500 participants.

Study design
This is an interventional study planning to enroll 500 participants. It compares Izalontamab Brengitecan to standard chemotherapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Progression-Free Survival will be measured for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~500 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Iza-brenCarboplatinCisplatinPemetrexed

At a glance

Recruiting sites
39 of 186 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recommended Phase 3 Dose (RP3D) of BMS-986507
Measured over Approximately 3 months after the first dose
+1 more outcome measured

Conditions

Non-Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell CarcinomaSoluble Epidermal Growth Factor Receptor

Where it's being run

186 sites across 122 states
Germany6
Taiwan6
New York4
France4
Italy4
Romania4
Seoul-teukbyeolsi [Seoul]4
Madrid, Comunidad de4

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Non-squamous NSCLC, not amenable to treatment in curative intent.
Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).

Exclusion

Inadequate organ function and/or bone marrow reserve.
Leptomeningeal metastases or spinal cord compression.
Poorly controlled systemic medical conditions.

What this trial measures

  • Recommended Phase 3 Dose (RP3D) of BMS-986507Approximately 3 months after the first dose

    Phase 2

  • Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)Up to 3 years

    Phase 3